Monday, September 26, 2022
wellness India Expo
Home Tags ICRA

Tag: ICRA

Revenue growth of hospitals to be moderate in FY2023: ICRA study

Aggregate occupancy for the sample set to be ~60-62% in FY2023; on a YoY basis, given the high base of FY2022, this translates to revenue growth of over 12%

Indian pharma companies to grow by 6-7% in FY2023: ICRA study

Headwinds related to pricing pressures in the US generics market and rising raw material costs will result in contraction of sample set profit margins in FY2023

Omicron hits elective surgeries, yet hospitals to report robust revenue in...

Given the relatively higher transmissibility of Omicron, large number of healthcare workers have also been infected with Covid-19 which might impact hospital operations to a certain extent

Diagnostic players to deliver double-digit revenue growth in FY2022: ICRA

ICRA predicts that prices of diagnostic tests are likely to stabilize at current levels due to focus on volume growth and higher competitive intensity from unorganized players

Hospitals expected to report 20-22% revenue growth in FY2022: ICRA

Occupancies likely to improve to 61-63% in FY2022, from 52.5% in FY2021 due to higher hospitalisations on account of second wave of Covid-19 and YoY increase in number of elective procedures owing to less restrictive lockdown as well as higher vaccination coverage.....................

ECLGS 4.0 to support capacity creation in healthcare: ICRA

Removal of the Rs. 500 crore-cap of loan outstanding for eligibility under ECLGS 3.0 provides access to larger healthcare companies for creating additional capacities..........................

RBI’s INR 50,000 crore liquidity window to boost healthcare infrastructure: ICRA

Loan tenor being capped at three years could be an impediment in availing the facility given that most industry players have a relatively longer asset pay-back period..........................

Pharma sector revenue to remain healthy at 8-11% in FY-2022: ICRA

Minimal impact of Covid-19 on the Indian pharmaceutical industry owing to inelastic demand for drugs coupled with continued supply of APIs/KSM from China, which accounts for 60% of industry requirement......................

Syngene Q2 operations revenue stands at INR 519 Crore, up 12%...

The company posted quarterly total revenue of INR 533 Crore compared to INR 485 Crore in the corresponding quarter of last year. EBITDA for the quarter was up 6% to INR 169 Crore while PAT was up 2% to INR 84 Crore..................

Revenues of healthcare sector likely to witness a 15-20% decline, predicts...

Revenues of the healthcare sector likely to witness a 15-20% decline due to Covid-19, EBIDTA and debt protection ratio too may fall sharply